Does diagnosis of the metabolic syndrome detect further men at high risk of cardiovascular death beyond those identified by a conventional cardiovascular risk score? The DECODE Study: The Diabetes Epidemiology: Collaborative analysis Of Diagnostic Criteria in Europe (DECODE) Study Group

European Journal of Preventive Cardiology

Volumn 14, Issue 2, 2007, Pages 192-199

  Balkau, Beverley ^a  

^a INSERM   (France)

Author keywords

cardiovascular diseases; epidemiology; obesity; risk factors

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FATALITY; HAZARD RATIO; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; WAIST CIRCUMFERENCE;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; EUROPE; FOLLOW-UP STUDIES; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK FACTORS; TRIGLYCERIDES; WAIST-HIP RATIO;

EID: 34247465124     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000230107.78524.da     Document Type: Article

References (38)

1. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Report of a WHO Consultation. Geneva, Switzerland: World Health Organization; 1999.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
3. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, 3rd report (Adult Treatment Panel III), final report. Circulation 2002; 106: 3143–3421.
4. Proceedings of the American College of Endocrinology Insulin Resistance Syndrome Conference. Washington, DC, USA. 25–26 August 2002. Endocr Pract 2003; 9 (Suppl 2):236–252.
5. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C$, American Heart Association/National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433–438.
6. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabetic Med 1999; 16: 442–443.
7. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–689.
8. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–2716.
9. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care 2002; 25: 1790–1794.
10. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, Howard BV, the Strong Heart Study. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American indians: the Strong Heart Study. Diabetes Care 2003; 26: 861–867.
11. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414–419.
12. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP, San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110: 1251–1257.
13. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, et al. 4S Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136–141.
14. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non-diabetic European men and women. Arch Intern Med 2004; 164: 1066–1076.
15. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245–1250.
16. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27: 2676–2681.
17. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities study. Diabetes Care 2005; 28: 385–390.
18. Mykkanen L, Kuusisto J, Pyorala K, Laakso M. Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. Diabetologia 1993; 36: 553–559.
19. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes 2002; 51: 3120–3127.
20. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 156: 1070–1077.
21. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM, San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care 2003; 26: 3153–3159.
22. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. A summary of the evidence. Diabetes Care 2005; 28: 1769–1778.
23. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CDA, Bouter LM, Heine RJ. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112: 666–673.
24. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006; 332: 878–882.
25. Alberti KGMM, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome — a new worldwide definition. Lancet 2005; 24: 1059–1062.
26. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. American Heart Association/National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–2752.
27. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al., and the SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.
28. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003; 10 (Suppl 1):S1–S78.
29. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000; 102: 179–184.
30. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617–621.
31. The DECODE Study Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26: 688–696.
32. DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia 2003; 46: 608–661.
33. International Classification of Diseases, Injuries and Causes of Death. Revision 9. Geneva: World Health Organization; 1997.
34. International Classification of Diseases, Injuries and Causes of Death. Revision 10. Geneva: World Health Organization; 1993.
35. Balkau B, Vernay M, Mhamdi L, Novak M, Arondel D, Vol S, et al. DESIR Study Group. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French DESIR study. Diabetes Metabol 2003; 29: 526–532.
36. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense H-W, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2362–2369.
37. Hillier TA, Rousseau A, Lange C, Lepinay P, Cailleau M, Novak M, et al. Practical way to assess metabolic syndrome using a continuous score obtained from principal components analysis: The DESIR Cohort. Diabetologia 2006; 49: 1528–1535.
38. Qiao Q, Jousilahti P, Eriksson J, Tuomilehto J. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. Diabetes Care 2003; 26: 2910–2914